Verastem Oncology, a biopharmaceutical company focused on RAS/MAPK pathway-driven cancers, is set to participate in several investor conferences in May. The company will present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20 at 12:00 pm ET, and the 2025 RBC Capital Markets Global Healthcare Conference on the same day at 3:35 pm ET. They will also join the Alliance Global Partners/A.G.P.'s Annual Healthcare Company Showcase for a virtual chat on May 21 at 10:20 am ET.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verastem Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250501095515) on May 01, 2025, and is solely responsible for the information contained therein.